Andrew Kennedy, Ph.D.Head of Peptides at Achilles Therapeutics UK Limited
Dr. Andrew Kennedy is the Head of Peptides for Achilles Therapeutics and an expert in peptide synthesis, process development and manufacture. After completing his PhD in Organic Chemistry at the University of Glasgow under the supervision of Professor Graeme Cooke, he then went on to specialize in peptide chemistry with Almac Sciences based in Edinburgh. Dr. Kennedy has held several senior scientist positions over the years in the chemical industry, and also the medical devices field, focusing on verification and validation of novel medical devices and release of products to market. More recently he held the position of Global Product Manager for the Peptides Business of Gyros Protein Technologies, managing their portfolio of peptide synthesizers, reagents and consumables. Currently, Dr Kennedy leads the peptide team at Achilles Therapeutics based in London, specialising in the synthesis of neoantigen peptides.